X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (126830) 126830
Newspaper Article (600) 600
Magazine Article (297) 297
Newsletter (261) 261
Book / eBook (134) 134
Government Document (112) 112
Book Chapter (87) 87
Conference Proceeding (50) 50
Web Resource (49) 49
Dissertation (47) 47
Publication (19) 19
Book Review (16) 16
Streaming Video (11) 11
Reference (3) 3
Paper (2) 2
Trade Publication Article (2) 2
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (117566) 117566
female (89719) 89719
oncology (59407) 59407
breast neoplasms - drug therapy (52792) 52792
breast cancer (49501) 49501
middle aged (38315) 38315
cancer (36980) 36980
breast neoplasms - pathology (31956) 31956
aged (29169) 29169
adult (29090) 29090
animals (27918) 27918
breast-cancer (26058) 26058
cell line, tumor (22975) 22975
chemotherapy (22799) 22799
male (17930) 17930
breast neoplasms - metabolism (16838) 16838
mice (16228) 16228
metastasis (15639) 15639
tumors (15199) 15199
care and treatment (14993) 14993
research (14839) 14839
antineoplastic agents - therapeutic use (14410) 14410
prognosis (14237) 14237
expression (14033) 14033
apoptosis (13985) 13985
antineoplastic combined chemotherapy protocols - therapeutic use (13680) 13680
breast neoplasms - genetics (12885) 12885
treatment outcome (12873) 12873
therapy (11673) 11673
health aspects (11503) 11503
antineoplastic agents - pharmacology (10976) 10976
analysis (10808) 10808
cancer therapies (9623) 9623
gene expression (9577) 9577
medicine & public health (9493) 9493
neoplasms - drug therapy (9353) 9353
pharmacology & pharmacy (9303) 9303
aged, 80 and over (9100) 9100
proteins (8840) 8840
cell biology (8589) 8589
survival (8475) 8475
risk factors (8307) 8307
cell proliferation - drug effects (8040) 8040
apoptosis - drug effects (8022) 8022
neoplasm metastasis (7967) 7967
carcinoma (7885) 7885
biochemistry & molecular biology (7863) 7863
breast neoplasms - surgery (7816) 7816
chemotherapy, adjuvant (7572) 7572
neoplasm staging (7533) 7533
genetic aspects (7457) 7457
research article (7439) 7439
breast neoplasms - therapy (7187) 7187
medicine (7103) 7103
gene expression regulation, neoplastic (7066) 7066
tamoxifen (7031) 7031
drug therapy (7003) 7003
women (6918) 6918
breast neoplasms - mortality (6863) 6863
signal transduction (6704) 6704
growth (6688) 6688
cells (6583) 6583
surgery (6578) 6578
development and progression (6371) 6371
immunohistochemistry (6236) 6236
mice, nude (6220) 6220
trastuzumab (6118) 6118
disease-free survival (5847) 5847
kinases (5787) 5787
retrospective studies (5753) 5753
dose-response relationship, drug (5746) 5746
tamoxifen - therapeutic use (5651) 5651
time factors (5612) 5612
tumor cells, cultured (5578) 5578
patients (5371) 5371
multidisciplinary sciences (5367) 5367
hematology, oncology and palliative medicine (5363) 5363
cell proliferation (5299) 5299
combined modality therapy (5215) 5215
medical prognosis (5210) 5210
cancer research (5199) 5199
xenograft model antitumor assays (5167) 5167
studies (5142) 5142
in-vitro (5109) 5109
drug resistance, neoplasm (5053) 5053
oncology, experimental (5042) 5042
metastases (5033) 5033
medicine, research & experimental (5004) 5004
medical research (4992) 4992
estrogen (4957) 4957
mcf-7 cells (4956) 4956
mutation (4954) 4954
antineoplastic combined chemotherapy protocols - adverse effects (4935) 4935
receptor, erbb-2 - metabolism (4919) 4919
survival analysis (4915) 4915
risk (4905) 4905
antineoplastic agents - administration & dosage (4870) 4870
activation (4869) 4869
cell cycle (4851) 4851
follow-up studies (4843) 4843
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (74) 74
Online Resources - Online (45) 45
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (10) 10
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
New College (Ivey) - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (2) 2
Credit Valley Hospital - Special Collections (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Media Commons - Audio Visual (1) 1
Scarborough Hospital - Online (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (122802) 122802
Japanese (1955) 1955
German (1314) 1314
French (1181) 1181
Chinese (562) 562
Russian (502) 502
Italian (390) 390
Spanish (311) 311
Polish (170) 170
Portuguese (119) 119
Hungarian (100) 100
Dutch (98) 98
Danish (83) 83
Czech (50) 50
Swedish (44) 44
Hebrew (33) 33
Finnish (32) 32
Norwegian (30) 30
Korean (18) 18
Bulgarian (17) 17
Serbian (16) 16
Croatian (15) 15
Romanian (9) 9
Turkish (7) 7
Ukrainian (7) 7
Slovak (5) 5
Lithuanian (3) 3
Bosnian (2) 2
Arabic (1) 1
Icelandic (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature cell biology, ISSN 1476-4679, 2018, Volume 20, Issue 8, pp. 954 - 965
BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To... 
PATHWAY CHOICE | STRAND BREAK REPAIR | RESECTION | DAMAGE-RESPONSE | 53BP1 | CLASS-SWITCH RECOMBINATION | FANCONI-ANEMIA | DIFFERENTIAL EXPRESSION ANALYSIS | POLYMERASE-ZETA | TELOMERES | CELL BIOLOGY | Osteosarcoma - drug therapy | Mad2 Proteins - metabolism | Humans | Multiprotein Complexes | Ovarian Neoplasms - pathology | Bone Neoplasms - pathology | DNA Breaks, Double-Stranded | Bone Neoplasms - metabolism | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | Telomere-Binding Proteins - genetics | DNA End-Joining Repair | HEK293 Cells | Female | Bone Neoplasms - genetics | Ovarian Neoplasms - metabolism | Bone Neoplasms - drug therapy | BRCA1 Protein - deficiency | Telomere-Binding Proteins - metabolism | Ovarian Neoplasms - drug therapy | Osteosarcoma - metabolism | DNA-Binding Proteins | Tumor Suppressor p53-Binding Protein 1 - metabolism | Recombinational DNA Repair | Tumor Suppressor p53-Binding Protein 1 - genetics | Cisplatin - pharmacology | Breast Neoplasms - drug therapy | Proteins - genetics | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Proteins - metabolism | Breast Neoplasms - pathology | Mad2 Proteins - genetics | Cell Line, Tumor | Mice | Osteosarcoma - genetics | Cell Cycle Proteins | Osteosarcoma - pathology | Care and treatment | DNA | Cancer cells | Breast cancer | Genetic aspects | Research | Gene expression | Single-stranded DNA | DNA damage | Homologous recombination | Poly(ADP-ribose) | Homology | Genomes | Inactivation | Proteins | Ribose | Null cells | Deoxyribonucleic acid--DNA | BRCA2 protein | CRISPR | Deactivation | BRCA1 protein | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Oligosaccharides | Double-strand break repair | Screens | Cisplatin | Polymerase | Inhibitors | Prostate | Viability | Tumors | Telomere-Binding Proteins / metabolism | Osteosarcoma / genetics | Telomere-Binding Proteins / genetics | BRCA1 Protein / genetics | Cellular Biology | Genetics | Proteins / genetics | Osteosarcoma / drug therapy | Ovarian Neoplasms / genetics | Mad2 Proteins / genetics | Proteins / metabolism | Breast Neoplasms / drug therapy | Breast Neoplasms / metabolism | Tumor Suppressor p53-Binding Protein 1 / genetics | BRCA1 Protein / deficiency | Ovarian Neoplasms / metabolism | Mad2 Proteins / metabolism | Breast Neoplasms / pathology | Bone Neoplasms / genetics | Ovarian Neoplasms / pathology | Bone Neoplasms / pathology | Life Sciences | Bone Neoplasms / drug therapy | Ovarian Neoplasms / drug therapy | Osteosarcoma / metabolism | Biochemistry, Molecular Biology | Breast Neoplasms / genetics | Drug Resistance, Neoplasm / genetics | Osteosarcoma / pathology | Bone Neoplasms / metabolism | Poly(ADP-ribose) Polymerase Inhibitors / pharmacology | Cisplatin / pharmacology | Molecular biology | Tumor Suppressor p53-Binding Protein 1 / metabolism | Cancer
Journal Article
Seminars in Oncology, ISSN 0093-7754, 2015, Volume 42, Issue 6, pp. 801 - 819
.... Most of these molecular alterations promote multiple steps of carcinogenesis in FGFR oncogene-addicted cells, increasing cell proliferation, angiogenesis, and drug resistance... 
BREAST-CANCER | LUNG-CANCER | IN-VITRO | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | RESISTANCE | GENE AMPLIFICATION | POTENTIAL THERAPEUTIC TARGET | PROGNOSTIC-SIGNIFICANCE | ANTITUMOR-ACTIVITY | EXPRESSION | Neoplasms - metabolism | Gastrointestinal Neoplasms - genetics | Gastrointestinal Neoplasms - drug therapy | Humans | Brain Neoplasms - pathology | Fibroblast Growth Factors - genetics | Brain Neoplasms - metabolism | Head and Neck Neoplasms - metabolism | Breast Neoplasms - metabolism | Fibroblast Growth Factors - metabolism | Gastrointestinal Neoplasms - pathology | Glioblastoma - genetics | Receptors, Fibroblast Growth Factor - genetics | Female | Glioblastoma - metabolism | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Gastrointestinal Neoplasms - metabolism | Biomarkers, Tumor - analysis | Head and Neck Neoplasms - drug therapy | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Thoracic Neoplasms - pathology | Brain Neoplasms - genetics | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Thoracic Neoplasms - metabolism | Head and Neck Neoplasms - pathology | Neoplasms - drug therapy | Breast Neoplasms - genetics | Thoracic Neoplasms - genetics | Breast Neoplasms - pathology | Glioblastoma - pathology | Receptors, Fibroblast Growth Factor - metabolism | Head and Neck Neoplasms - genetics | Fibroblast Growth Factors - antagonists & inhibitors | Thoracic Neoplasms - drug therapy | Glioblastoma - drug therapy | Neoplasms - pathology | Drug Resistance, Neoplasm - physiology | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
EMBO molecular medicine, ISSN 1757-4684, 2014, Volume 6, Issue 10, pp. 1279 - 1293
Epithelial‐mesenchymal transition (EMT) is a reversible and dynamic process hypothesized to be co‐opted by carcinoma during invasion and metastasis. Yet, there... 
drug response | microarray | gene expression signature | epithelial‐mesenchymal transition | prognosis | Drug response | Epithelial-mesenchymal transition | Prognosis | Microarray | Gene expression signature | MOLECULAR SUBTYPES | MEDICINE, RESEARCH & EXPERIMENTAL | GENE-EXPRESSION SIGNATURE | STEM-CELLS | GENOMIC ANALYSES | OVARIAN-CANCER | NEGATIVE BREAST-CANCER | CLINICAL-RELEVANCE | MICRORNA CONTROL | CLAUDIN-LOW | epithelial-mesenchymal transition | SIGNATURE PREDICTS RESISTANCE | Lung Neoplasms - drug therapy | Oligonucleotide Array Sequence Analysis | Colorectal Neoplasms - genetics | Humans | Epithelial-Mesenchymal Transition - drug effects | Antineoplastic Agents - therapeutic use | Epithelial-Mesenchymal Transition - genetics | Ovarian Neoplasms - genetics | Urinary Bladder Neoplasms - genetics | Neoplasms - genetics | Colorectal Neoplasms - drug therapy | Female | Gene Expression Regulation, Neoplastic - drug effects | Ovarian Neoplasms - drug therapy | Lung Neoplasms - genetics | Stomach Neoplasms - genetics | Treatment Outcome | Transcriptome - drug effects | Transcriptome - genetics | Stomach Neoplasms - drug therapy | Urinary Bladder Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Cell Line, Tumor | Cancer patients | Chemotherapy | Patient outcomes | Stem cells | Development and progression | Drug therapy | Gene expression | Ovarian cancer | Cancer | Mesenchyme | Colorectal carcinoma | Genomes | Breast cancer | Metastasis | Kinases | Cancer therapies | Metastases | Breast carcinoma | Genotype & phenotype | Paclitaxel | Breast | Software | Tumors
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2011, Volume 81, Issue 1, pp. 126 - 134
Purpose To perform a comprehensive cognitive function (CF) assessment in patients who were relapse free after curative intent radiotherapy (RT... 
Radiology | Hematology, Oncology and Palliative Medicine | Squamous cell carcinoma of the head and neck | Chemotherapy | Neuropsychological testing | Radiotherapy | Cognitive dysfunction | PROPHYLACTIC CRANIAL IRRADIATION | ADJUVANT CHEMOTHERAPY | DRIVING PERFORMANCE | FOLLOW-UP | CELL LUNG-CANCER | BREAST-CANCER | NASOPHARYNGEAL CARCINOMA | ONCOLOGY | NEUROCOGNITIVE FUNCTION | LOW-GRADE GLIOMA | QUALITY-OF-LIFE | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Laryngeal Neoplasms - radiotherapy | Pharyngeal Neoplasms - radiotherapy | Cerebellum - radiation effects | Prospective Studies | Humans | Middle Aged | Male | Pharyngeal Neoplasms - drug therapy | Antineoplastic Agents - administration & dosage | Cognition - physiology | Laryngeal Neoplasms - drug therapy | Neoplasms, Squamous Cell - pathology | Carcinoma - drug therapy | Carcinoma - blood | Affect - physiology | Head and Neck Neoplasms - drug therapy | Cognition - drug effects | Neoplasms, Squamous Cell - blood | Head and Neck Neoplasms - pathology | Carcinoma, Squamous Cell | Neuropsychological Tests | Cognition Disorders - diagnosis | Memory Disorders - etiology | Hypopharyngeal Neoplasms - pathology | Quality of Life | Pharyngeal Neoplasms - pathology | Hypopharyngeal Neoplasms - drug therapy | Temporal Lobe - drug effects | Laryngeal Neoplasms - blood | Cerebellum - drug effects | Hypopharyngeal Neoplasms - blood | Cisplatin - administration & dosage | Feasibility Studies | Laryngeal Neoplasms - pathology | Squamous Cell Carcinoma of Head and Neck | Head and Neck Neoplasms - blood | Antineoplastic Agents - adverse effects | Cognition Disorders - etiology | Neoplasms, Squamous Cell - drug therapy | Neoplasms, Squamous Cell - radiotherapy | Female | Carcinoma - pathology | Cognition - radiation effects | Affect - drug effects | Pharyngeal Neoplasms - blood | Affect - radiation effects | Carcinoma - radiotherapy | Combined Modality Therapy - adverse effects | Head and Neck Neoplasms - radiotherapy | Hypopharyngeal Neoplasms - radiotherapy | Cisplatin - adverse effects | Aged | Combined Modality Therapy - methods | Temporal Lobe - radiation effects | Care and treatment | Squamous cell carcinoma | Cancer | BODY FLUIDS | HEAD | NERVOUS SYSTEM | RADIATION DOSES | MEDICINE | THERAPY | CEREBELLUM | RADIOLOGY AND NUCLEAR MEDICINE | RADIOTHERAPY | COMBINED THERAPY | BRAIN | RADIOLOGY | BLOOD | NEOPLASMS | BIOLOGICAL MATERIALS | CENTRAL NERVOUS SYSTEM | STANDARD OF LIVING | CHEMOTHERAPY | NUCLEAR MEDICINE | ORGANS | DISEASES | DOSES | CARCINOMAS | NECK | DOSIMETRY | BODY | MATERIALS
Journal Article
American Journal of Pathology, ISSN 0002-9440, 2010, Volume 177, Issue 4, pp. 1647 - 1656
Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer. Because PTEN opposes the downstream... 
ADJUVANT CHEMOTHERAPY | INHIBITION | THERAPY | PROTEIN | HUMAN-BREAST-CANCER | PATHWAY | MUTATIONS | PATHOLOGY | RECEPTORS | TRASTUZUMAB RESISTANCE | EXPRESSION | Lung Neoplasms - drug therapy | Receptors, Estrogen - metabolism | Receptor, ErbB-2 - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Immunoenzyme Techniques | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Ductal, Breast - drug therapy | Brain Neoplasms - mortality | Liver Neoplasms - secondary | Proto-Oncogene Proteins c-akt - metabolism | Carcinoma, Ductal, Breast - metabolism | PTEN Phosphohydrolase - genetics | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Survival Rate | Lymphatic Metastasis | Brain Neoplasms - drug therapy | Mutation - genetics | Breast Neoplasms - drug therapy | Class I Phosphatidylinositol 3-Kinases | Carcinoma, Lobular - metabolism | Trastuzumab | Bone Neoplasms - mortality | Phosphorylation | Prognosis | Receptor, ErbB-2 - metabolism | Phosphatidylinositol 3-Kinases - metabolism | Liver Neoplasms - mortality | Carcinoma, Ductal, Breast - mortality | Carcinoma, Lobular - mortality | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Brain Neoplasms - secondary | In Situ Hybridization | Lung Neoplasms - secondary | Adult | Female | Bone Neoplasms - drug therapy | Neoplasm Invasiveness | Liver Neoplasms - drug therapy | PTEN Phosphohydrolase - metabolism | Phosphatidylinositol 3-Kinases - genetics | Breast Neoplasms - mortality | Aged | Carcinoma, Lobular - drug therapy | Regular
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 21, pp. 2654 - 2663
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line... 
POLY(ADP-RIBOSE) POLYMERASE | CLEAR-CELL | ONCOLOGY | RESISTANCE | IMPROVED SURVIVAL | HOMOLOGOUS RECOMBINATION | CARCINOMA | CARRIERS | TUMORS | CHEMOTHERAPY | FEATURES | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2015, Volume 10, Issue 12, p. e0145754
... clinical response to their primary therapy, nearly half will develop disease recurrence within 18 months and the majority will die from disease recurrence within 5 years... 
CA-125 | MULTIDISCIPLINARY SCIENCES | EPITHELIAL OVARIAN-CANCER | Endometrial Neoplasms - mortality | Humans | Middle Aged | Ovarian Neoplasms - mortality | Genital Neoplasms, Female - drug therapy | DNA, Neoplasm - blood | Endometrial Neoplasms - genetics | Adult | Female | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Genital Neoplasms, Female - genetics | CA-125 Antigen - blood | Ovarian Neoplasms - blood | Genital Neoplasms, Female - blood | Mutation - genetics | Breast Neoplasms - drug therapy | Biomarkers, Tumor - blood | Genital Neoplasms, Female - mortality | Exome - genetics | Breast Neoplasms - genetics | Breast Neoplasms - blood | Breast Neoplasms - mortality | Endometrial Neoplasms - drug therapy | Neoplasm Recurrence, Local - genetics | Aged | Biomarkers, Tumor - genetics | DNA, Neoplasm - genetics | Endometrial Neoplasms - blood | Physiological aspects | Prognosis | Biological markers | Genital cancer | Tumors | Plasma | Scanning | Ovarian carcinoma | Fallopian tube | Cancer therapies | Ovarian cancer | Gene sequencing | Computed tomography | Surgery | Quality | Imaging | Endometrium | Deoxyribonucleic acid--DNA | DNA probes | Gynecology | Breast cancer | Patients | Survival | Obstetrics | Medicine | Lead time | Chemotherapy | Surveillance | Womens health | Biomarkers | Diagnostic systems | Mutation | Reproductive system | Uterine cancer | Peritoneum | Cancer | Deoxyribonucleic acid | DNA
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2015, Volume 33, Issue 3, pp. 244 - 250
Journal Article
Cancer chemotherapy and pharmacology, ISSN 1432-0843, 2019, Volume 84, Issue 3, pp. 487 - 499
.... While their function in hepatic metabolism of taxanes is well established, expression of these enzymes in solid tumors may play a role in the in situ metabolism of drugs as well, potentially... 
Intratumoral | Ritonavir | Paclitaxel | Docetaxel | CYP | Review | Journal Article | Medicine & Public Health | Oncology | Cancer Research | Pharmacology/Toxicology | PREGNANE-X RECEPTOR | IMMUNOHISTOCHEMICAL LOCALIZATION | DOCETAXEL RESISTANCE | CYP3A4 EXPRESSION | TARGETED THERAPIES | MESSENGER-RNA | ONCOLOGY | P450-MEDIATED METABOLISM | BIOLOGICAL-ACTIVITY | PHARMACOLOGY & PHARMACY | HIV-1 PROTEASE INHIBITOR | METABOLIZING-ENZYMES | Lung Neoplasms - drug therapy | Taxoids - pharmacology | Humans | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Male | Breast Neoplasms - enzymology | Female | Antineoplastic Agents - pharmacology | Cytochrome P-450 CYP2C8 - metabolism | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Endometrial Neoplasms - enzymology | Lung Neoplasms - enzymology | Neoplasms - enzymology | Breast Neoplasms - drug therapy | Ovarian Neoplasms - enzymology | Neoplasms - drug therapy | Breast Neoplasms - pathology | Cytochrome P-450 CYP3A - metabolism | Prostatic Neoplasms - enzymology | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Neoplasms - pathology | Antimitotic agents | Protease inhibitors | Proteases | Pharmacy | Cytochrome P-450 | Physiological aspects | Drugstores | Antineoplastic agents | Ovarian cancer | Cytochrome | Enzymes | Cytochrome P450 | Proteinase inhibitors | Taxane | Metabolism | Anticancer properties | Antitumor agents | Lungs | Drug metabolism | Breast | Solid tumors | Taxanes | Prostate | Endometrium | Tumors | Cytochromes P450
Journal Article